Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

It has been brought to the publisher's attention that the following errors were made in the above article published in Seminars in Liver Disease, volume 44, Number 1 (DOI: 10.1055/a-2242-7543):

[Figure 3] and [Table 3], washout period data derived from Nordness et al. is noted to be 4 months instead of the correct 8 days.

On page 87 paragraph 5, sentence 10, the original sentence reads “In fact, the two fatalities occurred after the longest washout periods,^89,95 whereas three patients with washout periods of a week or less experienced no rejection.⁷⁹”

The corrected line is: “In fact, one of the two fatalities occurred after the longest washout periods,^89,95 whereas three patients with washout periods of a week or less experienced no rejection.⁷⁹”

All the above errors have been corrected in the HTML version of the article.

The corrected figure and table are depicted below. The error does not change the conclusion of the article.

Fig. 3 The washout period of all reported patients who had immune checkpoint inhibitors as bridging or downstaging therapy before liver transplant for hepatocellular carcinoma, divided into whether liver allograft rejection happened. Red: patients who died from rejection. Green: data from Chouik et al,⁹⁸ Solino et al,⁸⁸ and Sogbe et al,⁸⁵ where the exact washout period was not reported.

Table 3 All reported patients so far who had immune checkpoint inhibitors as bridging or downstaging therapy before liver transplant for hepatocellular carcinoma

Author and year	Age	Sex (M/F)	Regimen	Length of treatment	Washout period	Rejection	Survival	Follow-up length
Chouik 202398	57	M	Atezolizumab/Bevacizumab	18 cycles	Not reported, around 2 months	No	Yes	10 months
Rudolph 202391	47	F	Nivolumab	7 doses	55 days	No	Yes	48 months
Schmiderer 202390	63	M	Atezolizumab/Bevacizumab	6 months	6 weeks	No	Yes	12 months
Tow 202299	na	M	Nivolumab	8 weeks	6 weeks	Yes	Yes	22 days
Aby 202296	64	M	Nivolumab	23 cycles	16 days	Yes	Yes	16 months
Qiao 202182	53 (average)	M/F 7/0 patients	Pembrolizumab	1–5 cycles	1.3 months	1/7	Yes	15 days
Schnickel 202281 Dave 202294 Dehghan 2021[c] 83	61	F	Nivolumab	18 months	5 weeks	Yes[c]	Yes	38 months
	65	M	Nivolumab	8 months	10 days	Yes	Yes	13 months
	71	M	Nivolumab	8 months	3 months	No	Yes	16 months
	65	F	Nivolumab	12 months	4 months	No	Yes	11 months
	68	M	Nivolumab	12 months	6 months	No	No[a]	2 months
Abdelrahim 202297	66	M	Atezolizumab/Bevacizumab	6 cycles	8 weeks	No	Yes	1 year
Kang 202293	14	M	Pembrolizumab	9 weeks	138 days	No	Yes	4 years
Kang 202292	23	F	Nivolumab	6 months	6 months	No	Yes	6 months
Chen 202195	39	M	Toripalimab	10 cycles	93 days	Yes	No[b]	71 hours
Nordness 202089	65	M	Nivolumab	22 months	8 days	Yes	No[b]	10 days
Chen 202180	64	M	Nivolumab	1 cycle	7 days	No	Yes	26 months
	47	F	Nivolumab	1 cycle	122 days	No	Yes	9 months
	50	M	Nivolumab	1 cycle	62 days	No	Yes	8 months
	38	M	Nivolumab	6 cycles	59 days	No	Yes	13 months
	67	M	Nivolumab	6 cycles	67 days	No	Yes	7 months
Solino 202388	68	M	Atezolizumab/Bevacizumab	6 cycles	Not reported, around 2 months	No	Yes	14 months
Lizaola-Mayo 202187	63	M	Ipilimumab and Nivolumab	6 months	9 weeks	No	Yes	6 months
Schwacha-Eipper 202086	62	M	Nivolumab	34 cycles	15 weeks	No	Yes	12 months
Sogbe 202185	61	M	Durvalumab	15 months	Not reported, > 3 months	No	Yes	24 months
Tabrizian 202179	69	M	Nivolumab	21 cycles	18 days	No	Yes	23 months
	56	F	Nivolumab	8 cycles	22 days	No	Yes	22 months
	58	M	Nivolumab	32 cycles	1 day	No	Yes	22 months
	63	M	Nivolumab	4 cycles	2 days	No	Yes	21 months
	30	M	Nivolumab	25 cycles	22 days	Yes	Yes	16 months
	63	M	Nivolumab	4 cycles	13 days	No	Yes	14 months
	66	M	Nivolumab	9 cycles	253 days	No	Yes	14 months
	55	F	Nivolumab	12 cycles	7 days	No	Yes	8 months
	53	F	Nivolumab	2 cycles	30 days	No	Yes	8 months
Peterson 202184	68	M	Nivolumab	6 months	10 months	No	Yes	7 months

^a Death due to cardiac event with functioning liver allograft.

^b Death due to rejection and graft failure.

^c Salvaged with retransplantation.

Publication History

Article published online:
05 June 2024